[
    [
        {
            "time": "2023-03-21",
            "original_text": "角膜塑形镜利于儿童近视防控，重点推荐欧普康视、昊海生科等【东吴医药朱国广团队|0321周报】",
            "features": {
                "keywords": [
                    "角膜塑形镜",
                    "儿童近视",
                    "欧普康视",
                    "昊海生科"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "眼科"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "角膜塑形镜利于儿童近视防控，重点推荐欧普康视、昊海生科等【东吴医药朱国广团队|0321周报】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "下周操盘攻略：市场处于存量博弈的平静期，未来仍以结构性行情为主",
            "features": {
                "keywords": [
                    "存量博弈",
                    "结构性行情"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "下周操盘攻略：市场处于存量博弈的平静期，未来仍以结构性行情为主",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "警惕！市场猛烈砸盘，下周解禁股名单来了！医药大牛股赫然在列（附股） 解禁",
            "features": {
                "keywords": [
                    "砸盘",
                    "解禁股",
                    "医药大牛股"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "警惕！市场猛烈砸盘，下周解禁股名单来了！医药大牛股赫然在列（附股） 解禁",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "医药生物行业周报：基因细胞治疗CDMO黄金赛道有望孕育下一个药明生物",
            "features": {
                "keywords": [
                    "基因细胞治疗",
                    "CDMO",
                    "药明生物"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业周报：基因细胞治疗CDMO黄金赛道有望孕育下一个药明生物",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "4000万元！奥赛康和药明康德合作开发一款抗肿瘤新药！",
            "features": {
                "keywords": [
                    "奥赛康",
                    "药明康德",
                    "抗肿瘤新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "4000万元！奥赛康和药明康德合作开发一款抗肿瘤新药！",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "280亿元解禁潮来袭！3000亿“医药茅台”下周迎近80亿元解禁，这些股票也解禁压力大（附名单） 解禁",
            "features": {
                "keywords": [
                    "解禁潮",
                    "医药茅台",
                    "解禁压力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "280亿元解禁潮来袭！3000亿“医药茅台”下周迎近80亿元解禁，这些股票也解禁压力大（附名单） 解禁",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 10,
                "Headline_Structure": 10,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "惊雷！市场猛砸盘，定增热门龙头股，高瓴亏损超3亿元，网友：抄底的机会来了？下周解禁股名单来了，医药大牛股赫然在列（附股）\n亏损",
            "features": {
                "keywords": [
                    "砸盘",
                    "定增",
                    "高瓴",
                    "亏损",
                    "解禁股"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "惊雷！市场猛砸盘，定增热门龙头股，高瓴亏损超3亿元，网友：抄底的机会来了？下周解禁股名单来了，医药大牛股赫然在列（附股）\n亏损",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "CXO行业无海外订单回流风险，龙头业绩向好 调整后估值优势凸显",
            "features": {
                "keywords": [
                    "CXO",
                    "海外订单",
                    "龙头业绩",
                    "估值优势"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "CXO行业无海外订单回流风险，龙头业绩向好 调整后估值优势凸显",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]